New HSV-1 Research Raises Concerns About Brain Health
Scientists have discovered that HSV-1, the virus commonly responsible for cold sores, can alter the behavior of microglia, the brain’s immune cells.
These changes may interfere with the brain’s normal immune defenses and contribute to inflammation and neurological damage.
The findings highlight why HSV-1 research matters far beyond cold sores. Understanding how this virus interacts with the brain could help scientists investigate its potential role in neurodegenerative diseases, including Alzheimer’s.
HSV is more than a skin condition. We need better treatments, more research, and ultimately, a cure.
https://t.co/AJQOdnbXIB
It is time to end the neglect. Millions suffer in silence while herpes research remains critically underfunded. We need immediate action, prioritized funding, and a clear path toward a functional cure and effective vaccines.
#cureHSV@NIH@CDCgov @NIAIDNews @SenateGOP@SenateDems@NIHDirector_Jay
🧬 GENITAL HERPES MARKET EXPECTED TO GROW...AND NEW TREATMENTS ARE PART OF THE STORY
The global genital herpes market is projected to reach $3.15 BILLION by 2030, growing at an estimated 6% annual rate, according to a new market report.
But what matters most for people living with HSV isn't the market size — it's what is driving that growth.
Researchers and pharmaceutical companies are increasingly focusing on:
🔬 Next-generation antiviral therapies
💉 Preventive HSV vaccines
🧬 mRNA vaccine technology
💊 Long-acting treatments that could improve adherence
🧪 Faster and more accessible HSV diagnostics
📱 Digital sexual-health services and expanded access to care
The report highlights growing use of suppressive antiviral therapy and increasing demand for point-of-care HSV testing, while current treatments still include familiar antivirals such as acyclovir, valacyclovir and famciclovir.
One particularly important area is the development of new antiviral mechanisms beyond today's standard nucleoside analogues.
The report highlights the collaboration between Gilead Sciences and Assembly Biosciences, which includes development of next-generation therapies for viral diseases such as recurrent genital herpes. Assembly's HSV program includes long-acting helicase-primase inhibitors, a different antiviral approach from drugs such as acyclovir and valacyclovir.
Vaccine research is also part of the expanding landscape.
The article points to LVRNA101, an experimental multi-component mRNA vaccine candidate targeting HSV-2, being developed through a collaboration between Changchun Baike Biotechnology and Zhuhai Livanda Biotechnology in China. The candidate is designed to stimulate both antibody and cellular immune responses.
The bigger picture is clear:
HSV remains a major unmet medical need, and the pharmaceutical and biotech sectors increasingly see opportunities in better suppression, improved diagnostics, longer-lasting antivirals and vaccines.
⚠️ However, market growth does not mean a cure has arrived. Current approved antivirals manage HSV but do not eliminate latent virus from the body, while many next-generation approaches remain experimental.
For the HSV community, the encouraging part is that more research, competition and investment could ultimately mean more treatment options and better therapies than the ones patients have relied on for decades.
We need treatments that go beyond managing outbreaks.
People living with HSV deserve better antivirals, effective vaccines and ultimately, a cure. 🔥
#Herpes #HSV #HSV2 #GenitalHerpes #HerpesResearch #HerpesCure #Biotech
It is time to end the neglect. Millions suffer in silence while herpes research remains critically underfunded. We need immediate action, prioritized funding, and a clear path toward a functional cure and effective vaccines.
#cureHSV@NIH@CDCgov @NIAIDNews @SenateGOP@SenateDems@NIHDirector_Jay
Herpes is a silent epidemic. Chances are, you have one type or another. Educate yourself and stop cracking jokes. Herpes is not a punchline. #cureHSV@NIH@NIHDirector_Jay@CDCgov@CDCSTD@WHO
More than 3.8 billion people are living with HSV.
The HSV community isn't asking for sympathy, we're asking for progress.
We need better treatments.
We need more research.
We need a cure.
The millions of people living with HSV deserve to be seen, heard, and prioritized.
#HSV #Herpes #HerpesAwareness #EndTheStigma
If you suffer from cold sores, please sign this petition to accelerate the development of a functional cure called IM-250
https://t.co/o8j8JA406W via @Change
Do you suffer from cold sores, please sign this petition to accelerate the development of a treatment called IM-250.https://t.co/D6iwlfIzbU via @Change
Women are disproportionately affected by herpes. Herpes is an underfunded public health crisis. Ms. Gates, we are respectfully asking for your help. Please help fund herpes research for better treatments and cure.
#cureHSV@melindagates